patients have started their treatment, thus completing enrollment in this study. Subject, of course, to the duration of control for three patients still being treated, we expect topline results for the entire study in early 2021, while on the basis of these positive results, we are already preparing the continuation of the clinical development of AsiDNA™ through a phase 2 study in a selected indication with high medical needs."